10-Q: Quantumzyme Faces Going Concern Amidst Zero Revenue

Quantumzyme Corp. reported a net loss of $49,868 and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Summary

• Quantumzyme Corp. (formerly Reliant Services, Inc.) reported a net loss of $49,868 for the three months ended October 31, 2025, compared to a net loss of $65,523 for the same period in 2024.
• The company generated no revenue for both the three months ended October 31, 2025, and October 31, 2024.
• Operating expenses decreased to $39,196 for the quarter ended October 31, 2025, from $60,934 in the prior year, primarily due to reduced professional fees.
• Interest expense increased to $10,672 for the quarter ended October 31, 2025, from $4,589 in the prior year, driven by additional debt.
• Cash balance stood at a critically low $184 as of October 31, 2025, down from $584 on July 31, 2025.
• Total current liabilities increased to $490,769 as of October 31, 2025, from $441,301 on July 31, 2025.
• The company has an accumulated deficit of $5,686,435 as of October 31, 2025.
• Management identified substantial doubt about the company's ability to continue as a going concern due to recurring losses, accumulated deficit, and negative operating cash flows.
• Internal controls over financial reporting were deemed ineffective due to limited resources and lack of segregation of duties, constituting a material weakness.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, including zero revenue, critically low cash, a substantial working capital deficit, and a going concern warning. Significant internal control weaknesses further compound the negative outlook, indicating a high risk of business failure without immediate and substantial external funding.

Positives

• Net loss decreased to $49,868 for the quarter ended October 31, 2025, from $65,523 in the prior year, primarily due to lower operating expenses.
• Operating expenses decreased by approximately 35.7% year-over-year, from $60,934 to $39,196, mainly due to reduced professional fees.

Negatives

• The company reported zero revenue for the three months ended October 31, 2025, and 2024.
• Cash balance is critically low at $184 as of October 31, 2025.
• Total current liabilities increased to $490,769, resulting in a working capital deficit of $490,585.
• Accumulated deficit grew to $5,686,435 as of October 31, 2025.
• Net cash used in operating activities was $19,913 for the quarter, indicating continued cash burn.
• Interest expense increased significantly to $10,672 from $4,589 in the prior year, reflecting increased debt burden.
• The company is entirely dependent on external funding, with no firm agreements in place.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses, accumulated deficit, and negative cash flows from operations.
• Inability to obtain sufficient funding from the sale of securities, private investment, or a strategic partner could restrict growth and lead to suspension of operations.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• Disclosure controls and procedures were not effective due to limited internal resources and lack of multiple levels of transaction review.
• A material weakness in internal control over financial reporting exists due to insufficient dedicated resources, inexperienced personnel, and lack of segregation of duties.
• The absence of an audit committee or an independent audit committee financial expert is considered an important entity-level control weakness.
• Litigation is subject to inherent uncertainties, and adverse results could materially harm the business, though no material legal proceedings are currently known.

Future Outlook

The company expects operating expenses to increase in future years due to costs associated with increased operating activity under its business model. It is entirely dependent on attracting and receiving funding from either the sale of securities or outside sources such as private investment or a strategic partner to continue operations and growth. Failure to raise additional funds will adversely affect the business and may require suspension of operations, potentially leading to a loss for common stock purchasers. Any additional equity financing may involve substantial dilution to existing stockholders.

Management Comments

• "We expect our operating expenses will increase in future years as a result of the costs associated with the increased operating activity under our business model."
• "We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner."
• "We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all."
• "The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations."
• "Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock."
• "If we are unable to obtain necessary financing, we will likely be required to curtail our development plans. Any additional equity financing may involve substantial dilution to our then existing stockholders."
• Management believes that the financial statements and other information presented are materially correct, despite identified internal control weaknesses.

Industry Context

Quantumzyme Corp. initially focused on distributing office equipment but pivoted in February 2023 by acquiring assets in the Enzyme Catalyst biotransformation sector. Despite this strategic shift, the company has not generated any revenue from either business segment, indicating a significant challenge in commercializing its offerings or establishing market presence. The lack of revenue and severe liquidity issues suggest the company is far from being a viable player in either the office equipment distribution or the specialized biotechnology sector.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings. However, litigation is subject to inherent uncertainties, and adverse results could have a material adverse effect on the business.

Related Party Transactions

• Amounts due to related parties were $16,602 as of October 31, 2025, down from $17,002 on July 31, 2025. These amounts are non-interest bearing and due on demand.

Stakeholder Impact

• **Shareholders:** Face significant risk of substantial dilution if new equity financing is secured, or complete loss of investment if the company fails to obtain funding and suspends operations.
• **Creditors:** Face high risk of non-repayment given the company's severe liquidity issues, going concern warning, and increasing notes payable.
• **Employees:** Potential job insecurity and risk of layoffs if operations are curtailed or suspended due to lack of funding.
• **Management:** Under pressure to secure financing and address internal control deficiencies to ensure business continuity.

Next Steps

• Obtain sufficient capital and operations to implement remedial measures for internal control deficiencies, including assessing current duties, assigning additional duties, potentially hiring additional personnel, and considering an audit committee.
• Attract and receive funding from the sale of securities, private investment, or a strategic partner to address liquidity issues and support operations.

Key Dates

Recommendation

Quantumzyme Corp. presents an extremely high-risk investment profile. The company has zero revenue, critically low cash reserves ($184), a substantial working capital deficit ($490,585), and an accumulated deficit exceeding $5.6 million. Management explicitly states 'substantial doubt' about its ability to continue as a going concern and its complete dependence on external funding without any firm agreements. Furthermore, significant material weaknesses in internal financial controls and the absence of an audit committee indicate severe governance and operational deficiencies. These factors collectively point to an imminent risk of business failure and a near-certain loss for investors, warranting a 'strong sell' recommendation.

Keywords

Quantumzyme Corp, 10-Q, Quarterly Report, Financial Results, Net Loss, Going Concern, SEC Filing, Biotechnology, Enzyme Catalyst, Office Equipment, Working Capital Deficit, Internal Controls, Liquidity Risk, Funding Dependence